• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Iodobenzenes

Recent Advances in the Study of 4-(4-Iodophenyl)-3-Thiosemicarbazide (CAS: 41401-36-9): A Comprehensive Research Brief

The compound 4-(4-Iodophenyl)-3-Thiosemicarbazide (CAS: 41401-36-9) has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activities, and mechanistic insights. Recent studies highlight its role as a promising scaffold for developing novel antimicrobial and anticancer agents, with particular emphasis on its ability to modulate key enzymatic pathways.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthesis and optimization of 4-(4-Iodophenyl)-3-Thiosemicarbazide derivatives to enhance their bioactivity. The researchers employed a combination of computational modeling and high-throughput screening to identify derivatives with improved binding affinities for bacterial topoisomerase II, a critical target for antimicrobial therapy. The results demonstrated that specific structural modifications could significantly enhance the compound's inhibitory effects against drug-resistant bacterial strains, such as MRSA and Escherichia coli.

In another groundbreaking study, researchers investigated the anticancer potential of 4-(4-Iodophenyl)-3-Thiosemicarbazide in vitro and in vivo. The compound exhibited potent cytotoxic effects against several cancer cell lines, including breast (MCF-7) and lung (A549) carcinomas. Mechanistic studies revealed that the compound induces apoptosis via the mitochondrial pathway, accompanied by the upregulation of pro-apoptotic proteins like Bax and caspase-3. These findings were further supported by molecular docking analyses, which identified strong interactions between the compound and key apoptotic regulators.

Beyond its antimicrobial and anticancer properties, recent research has also explored the compound's potential as an inhibitor of amyloid-beta aggregation, a hallmark of Alzheimer's disease. A 2024 study in ACS Chemical Neuroscience reported that 4-(4-Iodophenyl)-3-Thiosemicarbazide effectively disrupts the formation of toxic amyloid-beta oligomers in vitro, suggesting its utility as a lead compound for neurodegenerative disease therapeutics. The study utilized advanced biophysical techniques, such as atomic force microscopy (AFM) and fluorescence spectroscopy, to validate these effects.

Despite these promising findings, challenges remain in optimizing the pharmacokinetic and pharmacodynamic profiles of 4-(4-Iodophenyl)-3-Thiosemicarbazide derivatives. Future research directions may include the development of prodrug formulations to enhance bioavailability and reduce off-target effects. Additionally, interdisciplinary collaborations between chemists, biologists, and clinicians will be critical to translating these preclinical findings into clinical applications.

In summary, 4-(4-Iodophenyl)-3-Thiosemicarbazide (CAS: 41401-36-9) represents a versatile and pharmacologically active scaffold with broad therapeutic potential. Continued research into its mechanisms of action and structural optimization will likely yield novel drug candidates for addressing unmet medical needs in infectious diseases, oncology, and neurodegeneration.

• 105941-44-4(Hydrazinecarbothioamide, N-phenyl-, hydrochloride (1:1))
• 76609-49-9(3-amino-1-4-(dimethylamino)phenylthiourea)
• 53305-98-9(Thiourea, N-(3-iodophenyl)-N'-phenyl-)
• 61335-32-8(Hydrazinecarbothioamide, N-(4-iodo-2-methylphenyl)-)
• 25759-84-6(Thiourea,N-(4-iodophenyl)-N'-phenyl-)
• 18879-80-6(1-(4-Iodophenyl)-2-thiourea)
• 5351-69-9(3-amino-1-phenylthiourea)
• 53305-89-8(Thiourea, N-(4-iodophenyl)-N'-methyl-)
• 53305-88-7(Thiourea, N-(3-iodophenyl)-N'-methyl-)
• 71058-36-1(Hydrazinecarbothioamide, N-(4-aminophenyl)-)